Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives

Iris van Doorn,Filip Eftimov,Luuk Wieske,Ivo van Schaik,Camiel Verhamme

DOI: https://doi.org/10.2147/tcrm.s360249

2024-02-15

Therapeutics and Clinical Risk Management

Abstract:Iris N van Doorn, 1 Filip Eftimov, 1 Luuk Wieske, 1, 2 Ivo N van Schaik, 1, 3 Camiel Verhamme 1 1 Department of Neurology and Clinical Neurophysiology, Amsterdam Neuroscience and University of Amsterdam, Amsterdam UMC, location AMC, the Netherlands; 2 Department of Clinical Neurophysiology, Sint Antonius Hospital, Nieuwegein, the Netherlands; 3 Sanquin Blood Supply Foundation, Amsterdam, the Netherlands Correspondence: Camiel Verhamme, Department of Neurology and Clinical Neurophysiology, Amsterdam Neuroscience and University of Amsterdam, Meibergdreef 9, Amsterdam UMC, location AMC, 1105AZ, the Netherlands, Email Diagnosing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) poses numerous challenges. The heterogeneous presentations of CIDP variants, its mimics, and the complexity of interpreting electrodiagnostic criteria are just a few of the many reasons for misdiagnoses. Early recognition and treatment are important to reduce the risk of irreversible axonal damage, which may lead to permanent disability. The diagnosis of CIDP is based on a combination of clinical symptoms, nerve conduction study findings that indicate demyelination, and other supportive criteria. In 2021, the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) published a revision on the most widely adopted guideline on the diagnosis and treatment of CIDP. This updated guideline now includes clinical and electrodiagnostic criteria for CIDP variants (previously termed atypical CIDP), updated supportive criteria, and sensory criteria as an integral part of the electrodiagnostic criteria. Due to its many rules and exceptions, this guideline is complex and misinterpretation of nerve conduction study findings remain common. CIDP is treatable with intravenous immunoglobulins, corticosteroids, and plasma exchange. The choice of therapy should be tailored to the individual patient's situation, taking into account the severity of symptoms, potential side effects, patient autonomy, and past treatments. Treatment responses should be evaluated as objectively as possible using disability and impairment scales. Applying these outcome measures consistently in clinical practice aids in recognizing the effectiveness (or lack thereof) of a treatment and facilitates timely consideration of alternative diagnoses or treatments. This review provides an overview of the current perspectives on the diagnostic process and first-line treatments for managing the disease. Keywords: CIDP, treatment, diagnosis, NCS, imaging Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous group of immune-mediated neuropathies characterized by progressive, monophasic or relapsing-remitting sensorimotor neuropathy, affecting both the peripheral nerves and nerve roots. CIDP incidence ranges from 0.5 to 3.3 cases per 100,000 people, which increases with age and is more common in males. 1–3 The clinical presentations of CIDP can be highly variable, encompassing both typical and atypical clinical variants. Nerve conduction studies (NCS) are the most important tool in the diagnosis of CIDP by demonstrating electrophysiological findings that support peripheral nerve demyelination. In daily practice, when NCS reveals abnormalities, it can be challenging to determine if a potentially "demyelinating" result indicates true peripheral nerve demyelination or if it stems from another cause, such as a reduced motor nerve conduction velocity (MNCV) in nerves with low compound muscle action potential (CMAP) due to the loss of large axonal fibers. 3,4 The rarity, heterogeneous presentation, lack of highly specific diagnostic tests and absence of blood-based biomarkers make diagnosing CIDP challenging. 5 Because CIDP is treatable 6 and because under- and misdiagnosis are common, delay in treatment or overtreatment is frequently seen. 7 Timely diagnosis and initiating treatment early may decrease the risk of permanent disability resulting from axonal damage. 8–11 The European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) published the revised 2021 guideline on the diagnosis and treatment of CIDP. 12 Despite advances in diagnostic criteria and tests, several challenges still persist. Distinguishing CIDP from other (demyelinating) neuropathies, especially in the case of a suspected CIDP variant, requires in-depth knowledge of the differential diagnosis, available diagnostic tests, and interpretation of diagnostic findings. There is ample evidence for the treatment of CIDP with immunomodulatory drugs, but tailoring the best treatment regimen to the individual patient continues to be a common challenge. Treatment response may differ between patients and timi -Abstract Truncated-

health care sciences & services